More on ATRA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $8.59 |
|
|||
| Open | $8.68 | ||||
| 52 Wk High | $40.80 | ||||
| 52 Wk Low | $12.45 | ||||
| Day High | $8.68 | ||||
| Day Low | $8.10 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 30,450 | ||||
- FDA accepts resubmitted BLA for Atara's tabelecleucel with 2027 target date
- Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
- Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
- Form 144 Atara Biotherapeutics, Filed by: Nguyen AnhCo
- Form 4 Atara Biotherapeutics, For: Aug 17 Filed by: Nguyen AnhCo
- TD Cowen Assumes Atara Biotherapeutics (ATRA) at Buy
- Form SCHEDULE 13G/A Atara Biotherapeutics, Filed by: Point72 Asset Management, L.P.
- Form 10-Q Atara Biotherapeutics, For: Jun 30
- ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 10c
- Form 8-K Atara Biotherapeutics, For: Aug 12
Entities mentioned with ATRA
- FDA | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- Citi | View Related Stories »
- Cowen & Co | View Related Stories »
- Canaccord Genuity | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
